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Abstract
Background: Nigeria has a significant burden of lymphatic filariasis (LF) caused by the parasite Wuchereria bancrofti. A major
concern to the expansion of the LF elimination programme is the risk of serious adverse events (SAEs) associated with the
use of ivermectin in areas co-endemic with Loa filariasis. To better understand this, as well as other factors that may impact
on LF elimination, we used Micro-stratification Overlap Mapping (MOM) to highlight the distribution and potential impact of
multiple disease interventions that geographically coincide in LF endemic areas and which will impact on LF and vice versa.
Methodology/Principal findings: LF data from the literature and Federal Ministry of Health (FMoH) were collated into a
database. LF prevalence distributions; predicted prevalence of loiasis; ongoing onchocerciasis community-directed
treatment with ivermectin (CDTi); and long-lasting insecticidal mosquito net (LLIN) distributions for malaria were
incorporated into overlay maps using geographical information system (GIS) software. LF was prevalent across most regions
of the country. The mean prevalence determined by circulating filarial antigen (CFA) was 14.0% (n = 134 locations), and by
microfilaria (Mf) was 8.2% (n = 162 locations). Overall, LF endemic areas geographically coincided with CDTi priority areas,
however, LLIN coverage was generally low (,50%) in areas where LF prevalence was high or co-endemic with L. loa.
Conclusions/Significance: The extensive database and series of maps produced in this study provide an important
overview for the LF Programme and will assist to maximize existing interventions, ensuring cost effective use of resources as
the programme scales up. Such information is a prerequisite for the LF programme, and will allow for other factors to be
included into planning, as well as monitoring and evaluation activities given the broad spectrum impact of the drugs used.
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Introduction
Lymphatic filariasis (LF) is one of the most debilitating neglected
tropical diseases (NTD) in the world [1]. It is caused by the
parasitic worms Wuchereria bancrofti, Brugia malayi and B. timori and is
transmitted by Anopheles, Culex, Aedes, Ochlerotatus and Mansoni
mosquitoes [1]. Wuchereria bancrofti is transmitted throughout the
tropics in Africa, Asia, the Pacific and the Americas while B. malayi
and B. timori are found in east and south Asia. The disease is
endemic in 73 countries with an estimated 120 million people
infected and 40 million people with clinical manifestations
including lymphoedema (elephantiasis) of the limbs and urogenital
disorders, especially hydrocele in men [2] [3]. In Africa, 34
countries are endemic, and Nigeria is believed to bear the highest
burden of LF, with an estimated 80 to 120 million people at risk
[3]–[][5].
The Global Programme to Eliminate LF (GPELF) was launched
in 2000 with the goal of eliminating LF as a public health problem
by 2020 [1]. The principal elimination strategy is to interrupt
transmission using Mass Drug Administration (MDA) with the
combinations of albendazole plus ivermectin or albendazole plus
diethylcarbamazine (DEC) administered once a year for at least
five consecutive years. [1]–[][3]. Overall, significant progress has
been made, however, the scale up of programmatic activities has
been slow in Africa, especially in countries with logistical
challenges, conflict, instability and fragile infrastructures [6]. The
wide and overlapping distribution of the filarial parasite Loa in
Africa [7] is also a major impediment due to the risk of severe
adverse events (SAEs) in co-infected individuals when treated with
ivermectin [8] [9].
These constraints pose significant problems for the national LF
programmes and GPELF with the potential to severely hinder the
2020 goal of LF elimination globally. To begin to address these
complexities, a number of specific objectives and strategies have
been developed. First, the GPELF strategic plan aims to achieve
full geographical coverage with MDA by 2016, targeting the
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countries with the highest burden, including Nigeria [1]. Second,
the use of integrated vector management (IVM) [10] is advocated
in malaria co-endemic areas where both diseases are transmitted
by Anopheles mosquitoes [11]. Finally, a provisional strategy for
interrupting LF transmission in loiasis endemic countries recently
developed recommends albendazole (400 mg) twice yearly in
combination with vector control in all co-endemic areas [12].
Finally, mapping LF and L. loa at the lowest possible administra-
tive unit is also considered important to identify small areas that
can be treated for LF using the most appropriate regimes to reduce
the risk of SAEs, which is considered to be highest when L. loa
microfilaremia (mf) prevalence is $20%.
The coordinated effort of global disease control programmes is
becoming increasingly important as many operate in the same
countries and distribute interventions that have multiple benefits
[13]–[16]. GPELF is likely to benefit from the activities of the
Global Malaria Programme, including the recent scale up of
insecticide treated/long-lasting insecticidal mosquito nets (ITNs/
LLINs) and indoor residual spraying (IRS) [11]. These interven-
tions have also been shown to impact LF transmission in a range of
ecological settings [17], thus more synergy between the pro-
grammes in Africa could optimize resources and increase the
impact on both diseases [15]–[18]. In countries such as Nigeria
where malaria and LF are co-endemic and both transmitted by
Anopheles mosquitoes [19] [20], the use of ITNs has shown to be
effective at reducing LF transmission in L. loa co-endemic areas
[21]. ITNs have also been successfully integrated with MDA
activities in Central Nigeria with report of an increase in ITN
ownership and retention [22] [23]. However, to take advantage of
these programmatic links, more data on LF vectors is critical as
there are many gaps in our knowledge as highlighted in the
Anopheles database recently compiled for Nigeria [19].
Integrating activities and combining resources across the various
NTD programmes will also have many advantages [13] [24]. For
example, the African Programme for Onchocerciasis Control
(APOC) has developed a sustainable community-directed treat-
ment with ivermectin (CDTi) for the parasitic disease caused by
the filarial worm Onchocerca volvulus, [25]–[27]. The CDTi
approach has been successful in reaching millions of people across
high transmission areas of onchocerciasis in Africa, and has also
been used to distribute other health interventions including LF
treatment and bed nets for malaria control [26]. Moreover, the
maps of CDTi priority areas highlight the potential geographical
overlap of onchocerciasis with LF, and it is likely that the wide and
frequent use of ivermectin has reduced transmission in co-endemic
areas [28]–[31]. However, the extent of this impact is yet to be
determined at a large scale and needs to be quantified so that
benefits from this and future NTD control programmes can be
better understood and fully exploited [5] [32]–[34].
These issues are particularly relevant for Nigeria, given the large
population at risk of W. bancrofti infection [3]–[5]. The National
Lymphatic Filariasis Elimination Programme (NLFEP) is yet to
complete LF mapping [3] [35] and will need significant financial
and technical support to scale up MDA activities across this large,
populous country. The aim of this paper, therefore, is to use the
Micro-stratification Overlap Mapping (MOM) approach [24] to
review and synthesize the current knowledge of the distribution of
W. bancrofti in Nigeria, and factors that will impact on the control
and elimination of LF such as loiasis co-endemicity, onchocerciasis
control programmes, and malaria bed net distributions. This
information is a prerequisite for effective planning and will help to
optimize the future LF MDA implementation strategy to ensure
safety, maximum cost effectiveness as well as impact.
Methods
Study location
Nigeria is a Federal Republic comprising 36 States and its
Federal Capital Territory, Abuja [35] [36]. The states are grouped
into six geopolitical zones, the North Central (NC), North East
(NE), North West (NW), South West (SW), South East (SE) and
South (SS). Nigeria covers an area of approximately 923,768 sq.
km, and has a large low plateau intersected by two major rivers,
the Niger and Benue, in the central region of the country
(Figure 1). It shares borders with Benin in the west, Chad and
Cameroon in the east, and Niger in the north. Its coast in the
south lies on the Gulf of Guinea on the Atlantic Ocean and Lagos,
the former capital, is an important port city. Nigeria is Africa’s
most populous country with the total population estimated to be
160 million in 2012, with approximately 50% living in urban
areas.
LF prevalence data
To review and synthesize the current knowledge of the human
distribution of LF in Nigeria, a systematic search for data in peer-
reviewed published literature and national reports was carried out.
The search was conducted using PubMed, JSTOR, Google,
SCOPUS and other online scientific and historical databases.
References were also obtained from the references listed within
articles, and then from the references within those articles.
Studies and reports with data on the prevalence of i) LF
infection as circulating filarial antigen (CFA) from using
immunochromatographic tests (ICTs), antibodies by ELISAs,
and microfilaria (Mf) from blood slides, and ii) disease cases
(hydrocele, lymphodema) [2] [37] were identified and collated into
a database. Information on the location/collection site (village,
local government area (LGA) and State), and time period (month,
year), was also collected for mapping and descriptive analyses.
Specific information on whether MDA for LF had been
administered prior to the LF prevalence measure was recorded
and considered in the analysis. The range of methods used to
detect LF in the different studies was recorded, as well as
information on the mosquito species, which was cross-checked
with the Nigerian Anopheles database [19].
The locations of the community or collection site were geo-
referenced using the latitude and longitude coordinates obtained
Author Summary
Nigeria is estimated to have the highest burden of
lymphatic filariasis (LF), a disease also known as elephan-
tiasis, which is transmitted by mosquitoes and caused by
the parasite Wuchereria bancrofti. The National LF Elimina-
tion Programme is planning to scale up the elimination
programme through mass drug administration of ivermec-
tin and albendazole. However, a major constraint to this
expansion is the risk of serious adverse events (SAEs)
associated with the use of ivermectin in areas co-endemic
with Loa, the causative agent of tropical eye worm (loiasis).
To better understand this and other factors that may
impact on LF elimination, we collated and mapped all
available LF data, and highlighted the overlaps with
predicted loiasis prevalence distributions, onchocerciasis
ivermectin treatment areas, and bed net distributions for
malaria. This study provides a baseline overview for the LF
Programme and will help to maximize existing disease
interventions, ensuring cost effective use of resources as
the programme scales up.
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from references directly or by cross-checking the names with data
from the GEOnet Names Server, Directory of Cities and Towns in
the World databases [38] [39]. The coordinates of the midpoint of
the LGA was used as a proxy for the locations that could not be
allocated exact latitude and longitude coordinates. This is
considered to be a limitation of the review and restricts any
accurate detailed mapping. It is also acknowledged that LF
prevalence distribution has a degree of bias as the data are based
on the locations selected by the investigators in the original study,
and does not take sampling methodologies between studies into
account, which may affect the outcome.
In addition, selected data from the Federal Ministry of Health
(FMoH) collected during LF mapping activities were collated and
included in the database. The LF data available for this study were
based on Mf prevalence rates collected in selected LGA sentinel
sites during baseline surveys in 31 LGAs across 18 States of
Nigeria. The WHO standard protocol was used to collect blood
samples at night and examined for the presence of Mf. The
coordinates of the midpoint of each LGA was used to map the LF
prevalence. A national LF endemicity map by LGA was also
available from the FMoH, which provided an overall CFA
prevalence based on ICT survey in each State carried out between
2000 and 2010. Specific LGA data is not publicly available and
not included in this database, however, the State-level information
on the number of LGAs surveyed, prevalence range and year of
survey is available in the recently published Master Plan for NTDs
[35].
All the relevant information was entered into an Excel
worksheet and data analysis was performed using Stata software
(version 12, StataCorp, Texas, USA). All data were mapped using
the geographical information systems (GIS) software ArcGIS 10.0
(ESRI, Redlands, CA) to produce maps of LF prevalence
distributions, and to examine the geographical overlaps with
loiasis-endemic areas, and the different intervention distributions.
Loiasis co-endemicity
To examine the potential extent of LF and L. loa co-endemicity,
the recent map of the predicted loiasis prevalence produced from a
Rapid Assessment Procedure of Loiasis (RAPLOA) based on eye
worm history carried out between 2004 and 2010 across Africa,
including Nigeria [7], was imported into ArcGIS. Three levels of
predicted loiasis prevalence were digitised (i.e. outlined, shaded)
based on the defined distribution boundaries, which included low
,20%, medium 20–40% and high .40% prevalence areas; the
Figure 1. Map of Nigeria and its geopolitical zones. North Central - Benue, FCT, Kogi, Kwara, Nasarawa, Niger, Plateau. North East - Adamawa,
Bauchi, Borno, Gombe, Taraba, Yobe. North West - Kaduna, Katsina, Kano, Kebbi, Sokoto, Jigawa,, Zamfara. South East - Abia, Anambra, Ebonyi,
Enugu, Imo. South - Akwa-Ibom, Bayelsa, Cross-River, Delta, Edo, Rivers. South West - Ekiti, Lagos, Osun, Ondo, Ogun, Oyo. Note: Elevation data based
on ETOPO2 global 2-minute gridded resolution from National Oceanic and Atmospheric Administration (NOAA) available from ESRI Redland, CA.
doi:10.1371/journal.pntd.0002416.g001
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latter is equivalent to mf prevalence of .20%. The different levels
of loiasis prevalence and the overlap with LF prevalence
distributions were highlighted to help identify potential low risk
(i.e. loiasis ,20%) and medium to high risk (i.e loiasis .20%) SAE
areas.
Interventions overlap maps
Onchocerciasis control programmes. To examine the
distribution of ivermectin and its association with LF and loiasis
endemicity, the CDTi map produced from REMO surveys
carried out in 2004 and 2005 [31] was imported into ArcGIS.
The CDTi priority (i.e. ivermectin treatment) areas were digitized,
and the overlap with LF and loiasis distributions highlighted. It
is acknowledged that the CDTI priority areas do not identify
the specific location, frequency and duration of ivermectin
distribution, but provide a broader overview of potential treat-
ment areas. Detailed data on treatment areas are not publicly
available.
Malaria bed net distributions. To examine the potential
impact of vector control in co-endemic areas, data on LLIN
coverage based on the percentage of households with at least one
LLIN for each geopolitical zone was obtained from the Malaria
Indicator Survey (MIS) carried out in 2010. The LLIN coverage
rates were based on data collected from 7200 households in 12
states across all geopolitical zones [40]. Coverage rates by each
zone were mapped based on three levels, which included ,25%,
25–50% .50%. The different levels of LLIN coverage and
overlap with LF and L. loa co-endemic areas were highlighted to
help identify areas that could potentially benefit from this
intervention.
Results
LF data summary
In total, 41 studies [41]–[81] from 68 published and unpub-
lished filariasis studies identified in the literature were found to
have examined the prevalence, clinical manifestations and
entomological aspects of LF in Nigeria (Table S1). The studies
excluded from the review had reported data on L. loa and/
onchocerciasis only. The majority of LF studies (n = 30) were
conducted post 2000 [41]–[69], nine studies were conducted
between 1980 and 2000 [70]–[78], and three studies were
conducted pre 1980 [79]–[81]. The studies indicate that LF is
present in 19 States across all six geopolitical zones of the country
(Figure 2a). The majority of studies were from the NC geopolitical
zone, with the most comprehensive studies carried out in Plateau
and Nassarawa States [49] [53] [54] [63] [66].
The FMoH sentinel site Mf prevalence data were carried out
more widely in 31 LGAs across 18 States. All information was
added to the database (Table S1) and mapped with the other
specific Mf data described above (Figure 2a). The FMoH national
endemicity map indicated that out of the 774 LGAs in Nigeria,
541 were classified as endemic, 164 were classified as non-endemic
and 69 remained to be mapped (Figure 2b). The related state-level
data are found in Nigeria Master Plan for NTDs [35].
The range of methods used to detect the presence of LF in
Nigeria included serological methods (using ICTs or ELISA),
parasitological methods (blood films for Mf) and physical
examination for clinical manifestations (lymphodema, hydrocele),
and were used either alone or in combination. Studies carried out
before the 1980s only used parasitological examination of blood
films, whereas post 2000, a combination of serology and
parasitological methods were most widely used (Table S1).
LF prevalence distribution
In total there were 258 individual data points from 152 unique
locations where the prevalence of W. bancrofti was measured by
CFA or Mf. The average CFA and Mf rates by State are
summarized in Table 1 and 2. The overall mean CFA prevalence
rate across the country was 14.0% (n= 134; range 0% to 66.0%),
and the overall mean Mf prevalence rate was 8.2% (n= 162; 0 to
47.4%). The CFA and Mf prevalence rates by geopolitical zones
indicate that the highest rates occur in the NC, NE, NW and SS
zones. The highest CFA prevalence rate recorded was 66%
recorded at Ogi-Utonkon, Ado LGA, Benue State, NC [64], while
the highest Mf rate was 47.4% recorded at Zing LGA, Taraba
State, NE [55] (Table S1).
Overall, there were marked differences in W. bancrofti
prevalence at sites that had not received MDA i.e. pre-MDA,
compared to those sites that had received MDA i.e. post-MDA.
The average CFA prevalence in pre-MDA sites, was 20.3%
(n= 68; range 0% to 66.0%), which was approximately 3 times
higher than the average CFA prevalence in post-MDA sites,
7.6% (n= 66, range 0.2% to 31.5%) (Figure 3a,b). The average
Mf prevalence in pre-MDA sites was 10.1% (n= 124; range 0%
to 47.4%), which was approximately 5 times higher than the
average Mf prevalence in post-MDA sites, 2.0% (n= 66, range
0% to 12.1%) (Figure 3c,d). The distribution of post-MDA sites
occur in the two States of Plateau and Nassarawa, and are the
result of an extensive MDA programme delivering the
combination of ivermectin and albendazole as detailed in the
study publications [49] [53] [54] [63]. Baseline LF mapping
was conducted in 1999 and 2000 in 30 LGAs of the two States,
and MDA launched in 2000, and monitored from 2000 to
2009. Details are contained in the specific reference [63] (Table
S1).
Clinical manifestations
The most extensive study on clinical manifestations was
conducted by Nwoke et al. [82], who used hydrocele as a clinical
marker to estimate LF prevalence. A rapid epidemiological
mapping survey (REM-LF) was conducted across 25 States and
536 villages in Nigeria. Details of the specific study sites are not
available, however, the survey found that hydrocele was absent in
339 (63.3%) villages, and present in 197 (36.8%) villages, which
were found to have different levels of hydrocele severity.
Hydrocele was absent in Jigawa and Kano (NW), and Ogun
(SW) States. Very few hydrocele cases (1–3%) were found in
northern Borno (NE), Kaduna and Zamfara (NW), Edo (SS), Imo
(SE),and in Ekiti, Ondo, Osun, Oyo (SW) States. The highest
hydrocele rates were found in the NE States of Adamawa, Bauchi,
Gombe, Taraba and southern Borno, in the NC states of Kogi,
Plateau, Nassarawa, and in the northern part of Akwa Ibom State
in the SS (Figure 2c) [82].
The clinical signs that were reported included limb lympho-
dema, hydrocele. chyluria and elephantiasis, and were from a few
specific areas of the country [45]–[49] [59]–[62][65] [68]–[71]
[74]–[75] [77]. For hydrocele, there were 22 sites with prevalence
data ranging from 0.1% to 50%, while for lymphodema, 12 sites
recorded prevalence rates ranging from 1% to 49%. The
prevalence of limb elephantiasis was also recorded in 5 sites,
which ranged from 1.7% to 11.8%. The distribution of these study
sites is shown in Figure 2c, together with the high hydrocele
prevalence states described by Nwoke et al. [82], and highlight the
geographical concordance with CFA and Mf distributions which
occur in the central south and eastern regions of the country
(Figure 2a).
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LF and loiasis co-endemicity
LF prevalence was examined in relation to the L. loa distribution
in Nigeria defined by the RAPLOA surveys reporting eye worm
history, which were carried out in 381 villages between 2002 and
2010 [7]. Loiasis was found predominately in the southern region
of the country, with the highest risk in east along the border with
Cameroon, which had a localized area .40% in the States of
Taraba and Benue (Figure 4). Overall, there was minimal
geographical overlap with the number of LF prevalence sites
determined by CFA. The majority of sites with medium to high LF
prevalence rates .25%, were found in low loiasis prevalence areas
(,20%) where the risk of SAEs are considered to be low
(Figure 4a). Similarly, there was minimal geographical overlap
with the number of LF prevalence sites determined by Mf,
however, more sites with medium to high LF prevalence rates
.25% were found in medium loiasis prevalence areas (20–40%)
where the risk of SAEs is potentially high (Figure 4b). The overlap
with the LF endemicity map available from the FMoH shows a
combination of endemic and non-endemic LGAs in the low
(,20%) to medium (20–40%) loiasis prevalence areas (Figure 4c).
Only LF non-endemic LGAs were found in the high risk loiasis
area (.40%), which is highlighted in the close up of the map in
Figure 4d.
Intervention overlap maps
The onchocerciasis CDTi priority areas [31] are shown in
Figure 5a, and illustrate that large areas across the central region
of the country are being targeted with ivermectin treatment. Since
1992, ivermectin has been distributed annually to 80% of the total
population at risk, estimated at ,38,331,140 people in 430
endemic LGAs [35]. The LF endemic areas to potentially benefit
from CDTi priority areas are extensive and include large areas of
NC, NW and NE zones of the country. The LF programme could
readily add albendazole to the ivermectin being distributed in
these areas (Figure 5b). The potential risks associated with
ivermectin treatment for O. volvulus are related to potential SAEs
Figure 2. LF prevalence data, endemicity status and disease data. a. CFA and Mf data. b. LF endemicity. c. Disease data. Note: Data source for
CFA, MF prevalence (2a) and disease (2c) data available in Table S1. LF endemicity map (2c) developed by FMoH.
doi:10.1371/journal.pntd.0002416.g002
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in areas where W. bancrofti and L. loa are co-endemic in the
southern region of the county, especially in the States of Benue,
Cross River, Ebonyi, Enugu, Osun, Ekiti and regions of Edo,
Ondo and Ogun States (Figure 5c).
The distribution of LLIN coverage across the six different
geopolitical zones is shown in Figure 5d. The highest LLIN
coverage occurred in the NE (61.8%) and NW (58.2%) zones,
followed by the SS (43.5%), SE (32.1%), NC (32.1%) and SW
(20.3%) zones respectively. This shows that the highest LLIN
coverage occurred in the northern region of the country where LF
does not appear to be highly endemic (Figure 5e). The lowest
LLIN coverage occurred across the southern region of the country,
which coincides with areas where both LF and loiasis are
considered endemic and co-endemic (Figure 5f).
Discussion
The database and series of maps produced in this study provide
critical information to the Nigerian National NTD Programme.
The LF Programme, specifically, will benefit as the implementa-
tion of MDA will be more effective in the coming years as it scales
up to reach national coverage with support from the government
and international stakeholders. This database represents the
largest geo-referenced source of data on W. bancrofti publicly
available for any country in Africa, and provides a basis on which
to add future programmatic and research data collected from
routine activities and systematic surveys in Nigeria over time.
Importantly, it highlights the few selected studies and large data
gaps on the burden of disease, which is an increasingly important
area for GPELF and the international community given the
significant social stigma and economic consequences of this
disabling disease [2]. This database also complements the
extensive Anopheles database recently developed by Okorie et al.
[19], which comprises all available information on the main
vectors of malaria and LF in Nigeria. The combination of the two
databases will help to prioritise programmatic activities by
appropriately targeting high LF prevalence areas, and by
identifying areas with data gaps where more information is
needed.
The LF prevalence data and maps clearly show the widespread
endemicity across the country, and the need to implement MDA
on a large scale with high levels of coverage. This will require
significant support as currently only 18,591,932 (17.5%) of the
targeted population are receiving MDA with ivermectin and
albendazole, with varying levels of coverage [35]. The impact of
MDA on LF transmission in most of the States and LGAs is yet to
be determined as this intervention has only started to expand.
However, detailed studies carried out in the States of Plateau and
Nassarawa have highlighted the effectiveness of this intervention
and the importance of documenting impact and progress through
systematic monitoring and evaluation [53] [63]. These results
suggest that Nigeria could significantly reduce W. bancrofti
transmission in the next few years with a collective effort and
commitment through increased human and financial resources
from both national and external donors and stakeholders. For
example, the concerted efforts geared towards the control of
onchocerciasis by APOC have made a huge impact on the
population by markedly reducing the prevalence and morbidity
associated with the disease [83].
The LF programme also needs to take advantage of the
interventions already being distributed by other programmes that
could enhance its efforts towards elimination. This study highlights
that large areas of Nigeria are CDTi priority areas and have
received multiple rounds of ivermectin for the control of O. volvulus
over the past decade [31][34]. It is likely that ivermectin has
already impacted on LF as shown elsewhere in West Africa [28]
[29], and possibly interrupted transmission in low prevalence
areas, especially those that have also received LLINs for malaria
control. More detailed studies examining the impact of ivermectin
on LF in Nigeria are important to fully appreciate its role in
reducing prevalence levels. The CDTi priority areas also provide
an opportunity for the LF programme to add albendazole to the
current ivermectin regimes, which will save time and lead to
considerable cost savings given the shared use of human resources
and infrastructure. Further, the collation and examination of
intervention data at State and LGA level using the MOM
approach [24] will help produce finer scale maps informing the
regional and local programmes of the risk and benefits, and actions
that need to be taken. It will also help determine if other NTDs,
such as the soil-transmitted helminths (STH), need to be
considered.
To date only mebendazole has been used for STH in Nigeria,
however, albendazole is being introduced in addition to
medendazole in 2013 by the FMoH and is also distributed during
Table 1. Summary of CFA prevalence by state.
Zone and State No. of sites
No. of persons
tested Mean (%) 95% CI (lower) 95% CI (Upper)
North Central
Benue 23 2189 12.9 11.5 14.4
Nassarawa 46 19026 11.4 11.0 11.9
Plateau 61 27325 16.5 16.1 16.9
Plateau, Nassarawa 1 4120 22.5 21.2 23.8
North West
Kaduna 1 341 10.0 7.0 13.7
South
Bayelsa 1 1803 11.3 9.9 12.9
Cross River 1 222 17.0 12.4 2.7
Total 134 55026 14.0 13.7 14.3
Note: All data included i.e. number of MDA rounds not taken into account.
doi:10.1371/journal.pntd.0002416.t001
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child health weeks, thus providing some indirect treatment in LF
endemic areas [35]. Integrating activities with the STH pro-
gramme will be essential as the expansion of the LF Programme
will also provide treatment for STH and support for the new STH
programme. Importantly, if albendazole is introduced and scaled
up for LF in the loiasis endemic regions the impact on both
diseases may be significant. Taking these factors into account is
important in a large, ecologically diverse and populous country
like Nigeria, where W. bancrofti is co-endemic with other diseases
and varies considerably in the different geopolitical zones and
ecological settings [20] [32]–[][][35]. This variability requires that
different intervention strategies should be developed and imple-
mented consonant with the most up to date information and
guided by WHO guidelines.
Table 2. Summary of Mf prevalence by state.
Zone and State No. of sites
No. of persons
tested Mean (%) 95% CI (lower) 95% CI (Upper)
North Central
Benue 3 1903 7.0 5.9 8.2
FCT* 1 - 0.0 - -
Kogi* 1 - 0.0 - -
Kwara* 1 - 0.0 - -
Kwara, Kogi, Plateau 1 172 13.9 9.1 20.0
Nassarawa 21 4431 1.1 0.8 1.5
Niger* 1 - 3.8 - -
Plateau 30 6322 3.4 3.0 3.9
North East
Adamawa* 1 - 1.2 - -
Bauchi 4 4114 1.2 0.8 1.5
Taraba 7 3966 23.5 22.2 24.9
Yobe* 3 - 0.0 - -
North West
Jigawa* 3 - 0.3 - -
Kaduna* 1 - 0.3 - -
Kano 6 180 1.0 0.1 4.0
Katsina 1 257 22.6 17.6 28.2
Kebbi* 1 - 0.0 - -
Zamfara* 3 - 4.6 - -
South East
Anambra* 1 - 18.8 - -
Ebonyi 1 1243 16.9 14.9 19.1
Imo 39 9131 12.8 12.1 13.5
Imo/Anambra 5 500 16.0 12.9 19.5
South South
Akwa Ibom* 1 - 17.6 - -
Bayelsa 2 2583 18.0 16.5 19.5
Cross River 11 1903 10.2 8.9 11.6
Edo* 1 - 2.2 - -
Rivers 5 2837 24.2 22.6 25.8
South West
Ekiti* 1 - 1.2 - -
Ogun 1 317 17.0 13.1 21.6
Ondo* 3 - 5.6 - -
Osun* 1 - 1.8 - -
Oyo 1 915 3.4 2.3 4.8
Total 162 40775 8.2 7.9 8.5
Note: All data included i.e. number of MDA rounds not taken into account.
*Value for number of persons tested not available.
Confidence intervals calculated in Stata software (version 12, StataCorp, Texas, USA).
doi:10.1371/journal.pntd.0002416.t002
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Nigeria, unlike several other L. loa endemic countries, has not
reported any SAEs associated with ivermectin treatment for O.
volvulus, which is shown to cover more than 90% of the L. loa area
[35]. The reason for this is unclear but may be related to the
different levels of endemicity and the strategies that have
successfully been used to address the risk [31]. It may also be
related to the extent of geographical overlap in high risk L. loa
areas, which appears to be less than countries in Central Africa
such as Cameroon and the Democratic Republic of Congo, where
SAEs have had a major negative impact on NTD programmes
[7]–[][9]. In Nigeria, LF and L. loa appear to be co-endemic at low
to medium prevalences (,40%) and only in the southern region of
country. This information will help focus the distribution of the
current WHO recommended alternative strategy of twice yearly
treatment albendazole and distribution of ITN/LLINs [12].
Coordination with STH programmes will be essential, especially
as new funding becomes available and programmes expand into
co-endemic areas [31] [32]. In the future new alternative drugs
and regimes such as the doxycycline an anti Wolbachia ’
macrofilaricide or adult sterilising agent [84]–[][86], may become
available for co-endemic area and fine scale mapping will help to
identify those populations most appropriate to target.
Strengthening linkages with the National Malaria Control
Programme will be crucial, especially as there has been significant
scale up of bed net distribution through a new campaign since
previously reported ITN coverage in 2005 [87] and the LLIN
coverage in 2010 reported here [88]. In mid-2012, nearly 50
million LLINs were reported to have been distributed across the
country representing 73% of the total number expected for
universal coverage distribution. [89,90]. This dramatic increase in
vector control has major implications for LF as bed nets have
shown to impact on W. bancrofti transmission, especially in
Anopheles-transmitted areas [17][21] [91][92]. Moreover, entomo-
logical data from a longitudinal study conducted in South East
Nigeria has showed that full coverage with LLINs can interrupt LF
transmission even in the absence of MDA [21]. More information
Figure 3. LF prevalence data pre-MDA and post-MDA. a. Pre-MDA CFA (n = 68). b. Post-MDA CFA (n = 66). c. Pre-MDA Mf (n = 124). d. Post-
MDA Mf (n = 38). Note: Data source for CFA, MF prevalence available in Table S1.
doi:10.1371/journal.pntd.0002416.g003
Mapping Lymphatic Filariasis in Nigeria
PLOS Neglected Tropical Diseases | www.plosntds.org 8 September 2013 | Volume 7 | Issue 9 | e2416
on Anopheles vectors and their susceptibility to insecticides being
used in vector control is urgently needed [19]. The role of
xenomonitoring should also be considered as it may be more
reliable and cost effective in the long term, especially in Nigeria
where there is a wide range of existing entomological capacity and
expertise that could be specifically developed and strengthened to
help monitor the elimination of the disease.
Conclusion
This MOM work builds on the recent study carried out in
Democratic Republic of Congo [24], which first used the new
overlap mapping approach to collate and map all available
country data on W. bancrofti, examine the extent of L. loa co-
endemicity and determine the risk and benefits of different
intervention strategies. Collectively the two studies address two
important countries in Africa with respect to the elimination of LF,
as they have the highest burdens of disease, collectively accounting
for more than 170 million people at risk. Furthermore, their LF
Programmes are yet to scale up to reach full national MDA
coverage taking into account the co-endemic areas of L. loa, which
may require alternative treatment strategies in selected areas, and
coordination with other NTD elimination and malaria control
programmes. We advocate that the MOM approach should be
used more widely over time and space, and at different
geographical scales to better monitor and understand the impact
of single and multiple interventions, and to assess progress towards
elimination of LF and other diseases. Such an approach is also
necessary for national planning purposes as well as increasing the
cost effectiveness and coordination of programmes where different
strategies are deployed, and where there have been previous
interventions which will impact on the goals of the LF programme.
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